Skip to Content
Notice

Request for Information: Solicits Public Input on the Renewal of “Combating the Silent Epidemic of Viral Hepatitis, Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis”

Action

Notice.

Summary

The Department of Health and Human Services (HHS) is seeking broad public input as it begins efforts to renew the 2011 Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis to include actions which can be undertaken over the course of the next three years, 2014-2016.

 

Table of Contents Back to Top

DATES: Back to Top

To be assured consideration, comments must be received at one of the addresses provided below, no later than 5:00 p.m. EST on July 5, 2013.

ADDRESSES: Back to Top

Electronic responses are strongly preferred and may be addressed to Corinna.Dan@hhs.gov. Written responses should be addressed to: U.S. Department of Health and Human Services, 200 Independence Ave. SW., Room 443-H, Washington, DC 20201. Attention: 2014 Viral Hepatitis Action Plan.

FOR FURTHER INFORMATION CONTACT: Back to Top

Corinna Dan, RN, MPH, Office of HIV/AIDS and Infectious Disease Policy, (202) 401-9581.

SUPPLEMENTARY INFORMATION: Back to Top

On May 12, 2011, the U.S. Department of Health and Human Services (HHS) issued Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis (Action Plan). The Action Plan details more than 150 actions to be undertaken over the course of three years by agencies and offices across HHS and partners at the Federal Bureau of Prisons, the U.S. Department of Veterans Affairs, and the U.S. Department of Housing and Urban Development that will improve the prevention, diagnosis, and treatment of viral hepatitis in the United States. A copy of the Action Plan and the Viral Hepatitis Action Plan Interagency Implementation Progress Report—Year 1 are available at http://www.aids.gov/news-and-events/hepatitis/.

The Action Plan put a spotlight on this silent epidemic and its growing impact in the United States, where as many as 5.3 million persons are living with chronic hepatitis B or C infection and millions more are at risk of infection. While viral hepatitis has been addressed by various federal research, prevention, care, and treatment programs, much of this work has been conducted independently, sometimes in isolation from other related efforts. Following the Institute of Medicine's (IOM) 2010 report, Hepatitis and Liver Cancer, which recommended steps to reduce the threats posed by hepatitis B and hepatitis C, Dr. Howard K. Koh, Assistant Secretary for Health, convened an interagency workgroup composed of subject matter experts from various HHS agencies to review the IOM recommendations and develop a comprehensive strategic viral hepatitis action plan that would:

  • Address IOM recommendations for viral hepatitis prevention, care, and treatment;
  • set forth actions to improve viral hepatitis prevention and ensure that infected persons are identified and provided care and treatment; and,
  • improve coordination of all activities related to viral hepatitis across HHS and promote collaborations with other government agencies and nongovernmental organizations.

Critical input into the Action Plan was also provided by stakeholders from other federal agencies, professional societies, and state, local, and community partners. The actions presented in the Action Plan represent efforts to be undertaken in calendar year 2011, 2012, or 2013. Some of the actions outlined in the Action Plan can be accomplished by using existing resources through improved coordination and integration, while others are subject to the availability of funds.

The Action Plan is organized into six priority areas which correspond to the 2010 IOM recommendations:

Priority 1—Educating Providers and Communities To Reduce Health Disparities Back to Top

GOAL 1.1Build a U.S. health care workforce prepared to prevent and diagnose viral hepatitis and provide care and treatment to infected persons.

GOAL 1.2Decrease health disparities by educating communities about the benefits of viral hepatitis prevention, care, and treatment.

Priority 2—Improving Testing, Care, and Treatment to Prevent Liver Disease and Cancer Back to Top

GOAL 2.1Identify persons infected with viral hepatitis early in the course of their disease.

GOAL 2.2Link and refer persons infected with viral hepatitis to care and treatment.

GOAL 2.3Improve access to and quality of care and treatment for persons infected with viral hepatitis.

GOAL 2.4Advance research to facilitate viral hepatitis prevention and enhance care and treatment for infected persons.

Priority 3—Strengthening Surveillance to Detect Viral Hepatitis Transmission and Disease Back to Top

GOAL 3.1Build a network of state and local surveillance systems with sufficient capacity to monitor viral hepatitis transmission and disease.

GOAL 3.2Monitor viral-hepatitis-associated health disparities.

GOAL 3.3Monitor provision and impact of viral hepatitis prevention, care, and treatment services.

GOAL 3.4Develop and implement new technologies and laboratory procedures to improve viral hepatitis surveillance.

Priority 4—Eliminating Transmission of Vaccine-Preventable Viral Hepatitis Back to Top

GOAL 4.1Eliminate mother-to-child transmission of hepatitis B.

GOAL 4.2Achieve universal hepatitis A and B vaccination for vulnerable adults.

GOAL 4.3Design and test new or improved viral hepatitis vaccines and determine the indications for their optimal use.

Priority 5—Reducing Viral Hepatitis Caused by Drug Use Behaviors Back to Top

GOAL 5.1Ensure that persons who inject drugs have access to viral hepatitis prevention, care, and treatment services.

GOAL 5.2Mobilize community resources to prevent viral hepatitis caused by injection drug use.

GOAL 5.3Provide persons who inject drugs with access to care and substance abuse treatment to prevent transmission and progression of disease.

GOAL 5.4Expand access to and delivery of hepatitis prevention, care, and treatment services in correctional settings.

GOAL 5.5Advance research to improve prevention of viral hepatitis among persons who use drugs.

Priority 6—Protecting Patients and Workers From Health Care-Associated Viral Hepatitis Back to Top

GOAL 6.1Reduce transmission of viral hepatitis to patients resulting from misuse of medical devices and drugs.

GOAL 6.2Reduce iatrogenic transmission of viral hepatitis associated with blood, organs, and tissues.

GOAL 6.3Reduce occupational transmission of viral hepatitis.

GOAL 6.4Enhance understanding of the preventable causes of viral hepatitis transmission in health care settings.

Following the Action Plan's release, agencies and offices across HHS began working to implement the actions assigned to them in the Action Plan. To support these efforts, HHS convened a Viral Hepatitis Action Plan Implementation Group (VHIG) and charged it with coordinating, supporting, and overseeing activities related to the Action Plan. The VHIG comprises representatives from across HHS and other federal agencies and is chaired by Dr. Ronald Valdiserri, Deputy Assistant Secretary for Health, Infectious Diseases.

The opportunity provided by the renewal of the Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis for 2014, 2015, 2016 offers many benefits such as:

  • Identification of measures to assess progress on addressing viral hepatitis in the U.S.;
  • identification of gaps in viral hepatitis services and data;
  • inclusion of new input from stakeholders;
  • recommendations for effective viral hepatitis program models; and,
  • application of lessons learned since the release of the 2011 Action Plan.

Accordingly, this request for information seeks public comment on several key dimensions of a renewed Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, including but not limited to the following:

1. Considering the six priority areas and related goals, please respond to the following questions:

a. Are there critical gaps in viral hepatitis activities which should be given a major focus in a renewed Action Plan? Provide background and rationale for their inclusion. These gaps may have been included in the 2011 Viral Hepatitis Action Plan or they may be new.

b. Are there effective models and best practices that should be considered for replication? Please include rationale for their use in the field/area of viral hepatitis.

2. What are the specific measures that should be used to track progress of implementation of the Viral Hepatitis Action Plan and/or the progress of addressing the epidemics of viral hepatitis? Provide background and rationale for the use of these measures.

3. What specific activities within and/or components of the Affordable Care Act offer substantial opportunities to support improved viral hepatitis health care services and data? Describe how this might evolve.

4. How can government better engage with non-governmental stakeholders around the implementation of the National Viral Hepatitis Action Plan? Provide examples/suggestions of how this could be integrated into a renewed Action Plan and its implementation.

5. What additional information not specifically addressed elsewhere in this RFI that would be important for the government to bear in mind in developing a renewed National Viral Hepatitis Action Plan?

Dated: May 21, 2013.

Ronald O. Valdiserri,

Deputy Assistant Secretary for Health, Infectious Diseases, Office of the Assistant Secretary for Health.

[FR Doc. 2013-13332 Filed 6-4-13; 8:45 am]

BILLING CODE 4150-28-P

Site Feedback